Cancer-Related Fatigue

2007 ◽  
Vol 5 (10) ◽  
pp. 1054 ◽  
Author(s):  
_ _
Keyword(s):  
Bone Marrow ◽  
Radiation Therapy ◽  
Cytotoxic Chemotherapy ◽  
Common Symptom ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Biologic Response ◽  
Dose Dense ◽  
Recent Version ◽  
Prevalence Of Cancer

Fatigue is a common symptom in patients with cancer and is nearly universal in those undergoing cytotoxic chemotherapy, radiation therapy, bone marrow transplantation, or treatment with biologic response modifiers. The problem, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. Patients perceive fatigue to be the most distressing symptom associated with cancer and its treatment, more distressing even than pain or nausea and vomiting, which, for most patients, can generally be managed with medications. For the most recent version of the guidelines, please visit NCCN.org

Cancer-Related Fatigue Clinical Practice Guidelines in Oncology

2003 ◽  
Vol 1 (3) ◽  
pp. 308 ◽  
Keyword(s):  
Clinical Practice ◽  
Cancer Survivors ◽  
Patient Care ◽  
Cancer Patients ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Cancer Related Fatigue ◽  
Dose Dense ◽  
Recent Version ◽  
Prevalence Of Cancer

The problem of cancer-related fatigue, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. To address the significant problem of cancer-related fatigue, the NCCN convened a panel of experts in the field of fatigue. The Cancer-Related Fatigue Clinical Practice Guidelines synthesize the available research and clinical experience in this field and provide recommendations for patient care. For the most recent version of the guidelines, please visit NCCN.org

Effect of Sucrose on Cisplatin-induced Fatigue-like Behavior in Mice: Comparison With Fructose and Glucose

2021 ◽  
Vol 1 (2) ◽  
pp. 95-102
Author(s):  
KAZUMI YOSHIZAWA ◽  
RUKA KURONO ◽  
HARUKA SATO ◽  
ERIKA ISHIJIMA ◽  
HARUKA NASU ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Anticancer Agents ◽  
Saline Control ◽  
Common Symptom ◽  
Antitumor Effects ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Running Activity ◽  
Glucose Intake

Background/Aim: Fatigue is the most common symptom in patients with cancer undergoing radiation therapy or cancer chemotherapy. However, cancer-related fatigue remains undertreated and poorly understood. Materials and Methods: Mice were administered a single dose of cisplatin (10 mg/kg, intraperitoneally) or saline (as a control) and then treated with sucrose, fructose, glucose (each at 500 or 5,000 mg/kg, orally), or saline (control) daily for 4 days. cisplatin-induced fatigue-like behavior was investigated by assessment of running activity on a treadmill. The influence of glucose intake on tumor growth was also examined in Lewis lung carcinoma (LLC)-bearing mice. Results: Administration of sucrose and glucose improved cisplatin-induced fatigue-like behavior in mice, whereas administration of fructose showed only slight antifatigue effects. Although glucose-fed mice showed increased tumor growth, this was balanced out by the powerful cytotoxicity of cisplatin. Conclusion: Sucrose, and especially glucose, may improve patient quality of life during treatment with anticancer agents by preventing fatigue without interfering with the antitumor effects of cisplatin.

scholarly journals Insights and Perspectives in the Clinical and Operational Management of Cancer-Related Anemia

2010 ◽  
Vol 8 (Suppl_7) ◽  
pp. S-38-S-55 ◽  
Author(s):  
Jennifer M. Hinkel ◽  
Edward C. Li ◽  
Stephen L. Sherman
Keyword(s):  
Quality Of Life ◽  
Radiation Therapy ◽  
Surgical Interventions ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Operational Management ◽  
Life Issues ◽  
Economic Perspectives ◽  
Cancer Related Anemia

Management of anemia in patients with cancer presents challenges from clinical, operational, and economic perspectives. Clinically, anemia in these patients may result from treatment (chemotherapy, radiation therapy, or surgical interventions) or from the malignancy itself. Anemia not only contributes to cancer-related fatigue and other quality of life issues, but also affects prognosis. From the operational perspective, a patient with cancer who is also anemic may consume more laboratory, pharmacy, and clinical resources than other patients with cancer.

The efficacy of placebo for the treatment of cancer-related fatigue: A systematic review and meta-analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23157-e23157
Author(s):  
Carmelia Maria Noia Barreto ◽  
Pedro Nazareth Aguiar ◽  
Daniel de Iracema Gomes Cubero ◽  
Auro Del Giglio
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Response Rate ◽  
Meta Analysis ◽  
Common Symptom ◽  
Future Studies ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Brief Fatigue Inventory ◽  
The Mean

e23157 Background: Cancer-related fatigue (CRF) is a common symptom among patients with cancer. The efficacy of placebo, however, was never the main objective of any meta-analysis. Predicting the efficacy of placebo may facilitate researchers in designing future clinical trials for the treatment of CRF. Methods: We performed a systematic review searching for prospective clinical trials comparing any treatment versus placebo for the treatment of CRF. We included studies that enrolled patients with any primary site of neoplasia and any stage of cancer. We excluded all studies that assessed fatigue related to any treatment. The primary endpoint of this study is the mean effect of placebo on fatigue according to the Functional Assessment of Chronic Illness (FACIT-F) and Brief Fatigue Inventory (BFI) scales. The secondary endpoint was the proportion of patients who reported improvement in fatigue (response rate). Results: We found 520 studies, and 29 studies with 3,758 participants were included in the meta-analysis. Placebo had a mean effect of +4.88 (95%CI +2.45 to +7.29) using the FACIT-F scale, although it was statistically worse than the interventions studied (p = 0.005). Using the BFI scale, placebo had an average effect of +0.64 (95%CI +0.02 to +1.30), although it was also worse than the other interventions studied (p = 0.002). In terms of the response rate, 29% (95%CI 25%–32%) of patients taking a placebo reported a significant improvement in CRF compared to 36% of patients treated with other interventions (p = 0.030). Conclusions: Placebo treatments had a significant effect on CRF, and predicting these effects may help design future studies for CRF.

scholarly journals Senior Adult Oncology Clinical Practice Guidelines in Oncology

2005 ◽  
Vol 3 (4) ◽  
pp. 572 ◽  
Keyword(s):  
Older Patients ◽  
Standard Treatment ◽  
The United States ◽  
Older Individuals ◽  
Patients With Cancer ◽  
Risks And Benefits ◽  
Geriatric Screening ◽  
Senior Adult ◽  
Recent Version ◽  
Prevalence Of Cancer

By 2030, researchers estimate that 20% of the U.S. population will be 65 years or older. More than 50% of all new cancers in the United States occur in this patient population. In addition, the increased incidence and prevalence of cancer in older patients and the increased lifespan of older adults mean that cancer in older individuals is becoming an increasingly common problem. Specific issues include geriatric screening and assessment, preventing or decreasing complications from therapy, accounting for disease-specific issues, and managing patients who cannot tolerate standard treatment. The NCCN Senior Adult Oncology Panel has developed guidelines for addressing these issues and for assessing the risks and benefits of treatment in older patients with cancer. For the most recent version of the guidelines, please visit NCCN.org

EEG-vigilance in patients with cancer-related fatigue syndrome in comparison to healthy controls

2010 ◽  
Vol 41 (01) ◽  
Author(s):  
S Olbrich ◽  
F Eplinius ◽  
S Claus ◽  
C Sander ◽  
M Trenner ◽  
...  
Keyword(s):  
Healthy Controls ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Fatigue Syndrome

Have Duchenne Muscular Dystrophy Patients an Increased Cancer Risk?

2021 ◽  
pp. 1-5
Author(s):  
Gian Luca Vita ◽  
Luisa Politano ◽  
Angela Berardinelli ◽  
Giuseppe Vita
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Systematic Investigation ◽  
Mdx Mice ◽  
True Incidence ◽  
Patients With Cancer ◽  
Dmd Gene ◽  
Age Range ◽  
Prevalence Of Cancer

Background: Increasing evidence suggests that Duchenne muscular dystrophy (DMD) gene is involved in the occurrence of different types of cancer. Moreover, development of sarcomas was reported in mdx mice, the murine model of DMD, in older age. So far, nine isolated DMD patients were reported with concomitant cancer, four of whom with rhabdomyosarcoma (RMS), but no systematic investigation was performed about the true incidence of cancer in DMD. Methods: All members of the Italian Association of Myology were asked about the occurrence of cancer in their DMD patients in the last 30 years. Results: Four DMD patients with cancer were reported after checking 2455 medical records. One developed brain tumour at the age of 35 years. Two patients had alveolar RMS at 14 and 17 years of age. The fourth patient had a benign enchondroma when 11-year-old. Conclusion: Prevalence of cancer in general in the Italian DMD patients does not seem to be different from that in the general population with the same age range. Although the small numbers herein presented do not allow definitive conclusion, the frequent occurrence of RMS in DMD patients raises an alert for basic researchers and clinicians. The role of DMD gene in cancer merits further investigations.

Cancer-related fatigue: an overview

2021 ◽  
Vol 30 (4) ◽  
pp. S36-S43
Author(s):  
Mohammed Al Maqbali
Keyword(s):  
Negative Impact ◽  
Management Strategies ◽  
Background Information ◽  
Clinical Settings ◽  
Measurement Scales ◽  
Major Life ◽  
Patients With Cancer ◽  
Cancer Related Fatigue ◽  
Diagnosis Of Cancer ◽  
Life Stressor

A diagnosis of cancer is a major life stressor that can affect the physiological, psychological and physical state of the person concerned. Fatigue is a particularly common and troubling symptom that has a negative impact on quality of life throughout all phases of treatment and stages of the illness. The aim of this review is to provide background information on cancer-related fatigue. This review discusses cancer-related fatigue (CRF) in terms of the definition, prevalence, risk factors, aetiology, and the measurement scales used. The differences between definitions of symptoms and relevant theories will be explored and discussed to help explain the variety of instruments used in its measurement. The prevalence of fatigue will be assessed by looking critically at the evidence of fatigue and the factors that affect it. Potential treatment and management strategies for CRF will also be discussed. Finally, there will be an overview of the instruments used to measure fatigue. This review also provides important evidence for measuring and managing CRF that can help nurses to understand fatigue among patients with cancer. Assessing CRF should be routinely undertaken in clinical settings to help identify the proper interventions, treatments and management to reduce fatigue among cancer patients.

scholarly journals A Randomized Controlled Trial of Home-Based Exercise for Cancer-Related Fatigue in Women During and After Chemotherapy With or Without Radiation Therapy

2010 ◽  
Vol 33 (4) ◽  
pp. 245-257 ◽  
Author(s):  
Marylin J. Dodd ◽  
Maria H. Cho ◽  
Christine Miaskowski ◽  
Patricia L. Painter ◽  
Steven M. Paul ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Radiation Therapy ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Cancer Related Fatigue ◽  
Home Based
Sign in / Sign up

Export Citation Format

Share Document